Purified anti-mouse IL-4 Antibody

Pricing & Availability
Clone
11B11 (See other available formats)
Regulatory Status
RUO
Other Names
Interleukin-4, Ia inducing factor (IaIF), B cell stimulating factor-1 (BSF-1), Hodgkin's cell growth factor (HCGF), Mast cell growth factor-2 (MCGF-2), Macrophage fusion factor (MFF), T cell growth factor-2 (TCGF-2)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
Cat # Size Price Quantity Check Availability Save
504101 50 µg £57
Check Availability


Need larger quantities of this item?
Request Bulk Quote
504102 500 µg £87
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IL-4 is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. IL-4 is a potent lymphoid cell growth factor which stimulates the growth and activation of certain B cells and T cells. IL-4 is important for regulation of T helper subset development.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Partially purified native mouse IL-4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

ELISA Capture - Quality tested
CyTOF® - Verified
IP, IHC, ICC - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 0.5-2.0 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IL-4 recombinant protein ranging from 250 to 2 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA1,2,10,13 or ELISPOT5 Capture: The purified 11B11 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD6-24G2 antibody (Cat. No. 504202) as the detecting antibody and recombinant mouse IL-4 (Cat. No. 575609) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.
Neutralization1-2,9,12: The 11B11 antibody can neutralize the bioactivity of natural or recombinant IL-4. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-4 bioactivity in vivo and in vitro (Cat. No. 504108).
Additional reported applications (for the relevant formats) include: immunoprecipitation16, immunohistochemical staining of formalin-fixed paraffin-embedded tissue sections8 and paraformaldehyde-fixed, saponin-treated frozen tissue sections6,7, and immunocytochemistry4.
Note: For testing mouse IL-4 in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 431101 to 431106) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Shirai A, et al. 1994. Cytokine 6:329. (ELISA, Neut)
  2. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA, Neut)
  3. Assenmacher M, et al. 1994. Eur. J. Immunol. 24:1097.
  4. Openshaw P, et al. 1995. J. Exp. Med. 182:1357. (ICC)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISA Capture)
  6. Litton M, et al. 1994. J. Immunol. Methods 175:47. (IHC)
  7. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC)
  8. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  9. Hara M, et al. 2001. J. Immunol. 166:3789. (Neut)
  10. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  11. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  12. Wang W, et al. 2007. J. Immunol. 178:4885. (Neut)
  13. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  14. Ohnmacht C, et al. 2008. Blood 113:2816. PubMed
  15. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  16. Zavorotinskaya T, et al. 2003. Mol. Ther. 7:155. (IP)
Product Citations
  1. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  2. Liu W, et al. 2022. Stem Cells Int. 2022:1052166. PubMed
  3. Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed
  4. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  5. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
  6. Abdel-Gadir A, et al. 2019. Nat Med. 25:1164. PubMed
  7. Lin F, et al. 2019. Sci Adv. 5:eaax1608. PubMed
  8. Berber E, et al. 2022. J Virol. 96:e0068822. PubMed
  9. Yang WL, et al. 2023. Nat Commun. 14:863. PubMed
  10. Zani F, et al. 2023. Nature. 615:705. PubMed
  11. Fang D, et al. 2018. J Exp Med. 215:2705. PubMed
  12. Yang J, et al. 2020. Front Immunol. 10:3048. PubMed
  13. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  14. Matthias J, et al. 2020. J Clin Invest. 130:4587. PubMed
  15. Crawford G, et al. 2018. Nat Immunol. 1.388194444. PubMed
  16. Liu W, et al. 2021. Stem Cell Res Ther. 12:153. PubMed
  17. Singh R, et al. 2017. J Immunol. 10.4049/jimmunol.1602010. PubMed
  18. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  19. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  20. Kaisar MMM, et al. 2018. PLoS Biol. 16:e2005504. PubMed
  21. Kölle J, et al. 2022. iScience. 25:104440. PubMed
  22. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  23. Wang Y, et al. 2021. Sci Transl Med. 13:. PubMed
  24. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
  25. He J, et al. 2021. Nat Commun. 12:4371. PubMed
  26. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  27. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
  28. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  29. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  30. Tan X, et al. 2021. Mol Microbiol. 116:498. PubMed
  31. Di Conza G, et al. 2021. Nat Immunol. 22:1403. PubMed
  32. Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed
  33. Thornton T, et al. 2016. Nat Commun. 7:10553. PubMed
  34. Hammer A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01922. PubMed
  35. Song K, et al. 2017. Oncotarget. 8:38554. PubMed
  36. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
  37. Xu G, et al. 2007. J Immunol. 179:5358. PubMed
  38. Sun Y, et al. 2021. Nat Commun. 12:5147. PubMed
  39. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  40. Kaushik DK, et al. 2019. J Clin Invest. 130. PubMed
  41. Lee B, et al. 2019. Front Immunol. 0.561805556. PubMed
  42. Voehringer C 2009. Blood. 113:2816. PubMed
  43. Lee JK, et al. 2021. Cell Mol Immunol. 18:1395. PubMed
  44. Umeda M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  45. Chen YH, et al. 2022. Arthritis Res Ther. 24:27. PubMed
RRID
AB_315315 (BioLegend Cat. No. 504101)
AB_315315 (BioLegend Cat. No. 504102)

Antigen Details

Structure
Cytokine; 15-19 kD (Mammalian)
Bioactivity
Differentiation of naïve CD4+ T cells to the TH2 type, proliferation/differentiation of activated B cells, expression of class II MHC antigens, and of low affinity IgE receptors in resting B cells
Cell Sources
Mast cells, T cells, bone marrow stromal cells
Cell Targets
B cells, T cells, monocytes, endothelial cells, fibroblasts
Receptors
Heterodimer IL-4Rα (CD124); γ-subunit (CD132) in common with IL-2R, IL-7R, IL-13R, IL-15R
Cell Type
Tregs
Biology Area
Immunology
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Boulay J, et al. 1992. Curr. Opin. Immunol. 4:294.
3. Dullens H, et al. 1991. In vivo 5:567.
4. Paul W. 1991. Blood 77:1859.

Regulation
Upregulated by IL-2, platelet activating factor; downregulated by TGF-β
Gene ID
16189 View all products for this Gene ID
UniProt
View information about IL-4 on UniProt.org
Go To Top Version: 4    Revision Date: 08/31/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account